Calcium, Phosphate, PTH, and Kidney Bone Disease — Advanced

Urgent haemodialysis with a low-calcium dialysate is the most appropriate immediate therapy in a patient with severe, symptomatic hypercalcaemia who is oliguric with very poor kidney function. Dialysis rapidly lowers serum calcium and is indicated when conventional measures are likely to be ineffective or unsafe (for example volume loading in oliguric/volume-overloaded patients, or when renal clearance of drugs is inadequate).

Why the others are less appropriate:
- IV saline + furosemide is a first-line approach in many severe hypercalcaemia cases with preserved urine output, but the patient is oliguric and hypotensive so aggressive volume loading may be ineffective or harmful.
- IV zoledronic acid is effective for lowering calcium in the following days but is renally excreted and may be contraindicated or require dose adjustment in severe renal impairment; it is not an immediate rescue therapy.
- IV hydrocortisone is useful in vitamin D–mediated hypercalcaemia (e.g. granulomatous disease) but is not first-line for severe, uraemic hypercalcaemia.
- Calcitonin has a rapid but modest and transient effect and should be used as an adjunct for short-term reduction; it is inadequate as sole therapy in severe symptomatic cases with renal failure.

The first step in managing very high PTH in CKD is to identify and correct reversible contributors: hyperphosphataemia, hypocalcaemia, vitamin D deficiency, inadequate dialysis or medication non-adherence. In this patient phosphate is elevated and contributes to secondary hyperparathyroidism; intensifying phosphate control (dietary measures, phosphate binders, dialysis prescription) and ensuring dialysis adequacy are appropriate initial strategies. Parathyroidectomy is reserved for refractory severe hyperparathyroidism despite medical therapy, or for significant symptoms/complications unresponsive to medical measures.

Why the others are less appropriate:
- Urgent parathyroidectomy is premature without optimising modifiable factors and attempting medical therapy.
- Immediate high-dose calcitriol risks hypercalcaemia and should be considered only after assessing and addressing phosphate and calcium and with monitoring; also many centres prefer selective vitamin D receptor activators.
- Bisphosphonates are not indicated for high-turnover secondary hyperparathyroidism and are potentially harmful in severe CKD unless specific indications exist for osteoporosis, with caution.
- Repeating PTH in 6 months without intervening on correctable drivers is inappropriate given the marked elevation and symptoms.

This presentation is typical of calciphylaxis (calcific uremic arteriolopathy). Initial management should be multidisciplinary: discontinue vitamin K antagonists (e.g. warfarin) because they are associated with increased risk, optimise mineral metabolism (reduce phosphate and avoid calcium loading), aggressive wound care, pain control and consider sodium thiosulfate as an adjunctive therapy. Prompt correction of modifiable risk factors is essential.

Why the others are less appropriate:
- Increasing calcium-containing binders will increase calcium load and may worsen vascular calcification—contraindicated.
- Systemic corticosteroids are not standard therapy for calciphylaxis; antibiotics only if there is infection, but steroids are not first-line.
- Bisphosphonates are not established as initial therapy for calciphylaxis and may not be appropriate in advanced CKD.
- Continuing warfarin is harmful; switching anticoagulation should be individualised, but immediate continuation until surgery is not advised; low-molecular-weight heparin may also carry risk and dosing is complex in ESRD.

Hungry bone syndrome after parathyroidectomy results from rapid influx of calcium into bone and presents with symptomatic hypocalcaemia. Immediate management is intravenous calcium replacement: an initial bolus of IV calcium gluconate followed by a continuous infusion often required, together with high-dose oral elemental calcium and active vitamin D (calcitriol) to facilitate calcium absorption and reduce ongoing bone uptake. Monitoring and adjustment are essential.

Why the others are less appropriate:
- Oral calcium alone is too slow and insufficient for symptomatic postoperative hypocalcaemia with neuromuscular signs.
- Bisphosphonates are contraindicated in acute hypocalcaemia as they further suppress bone resorption and will worsen hypocalcaemia.
- IV magnesium is used if hypomagnesaemia contributes but is not the primary therapy for hypocalcaemic tetany unless magnesium is low.
- High-dose oral phosphate would lower calcium further by precipitating calcium-phosphate; it is dangerous and not indicated.

This patient likely has tertiary hyperparathyroidism after transplantation characterised by autonomous parathyroid hypersecretion with hypercalcaemia and end-organ complications (stones, bone loss). Definitive therapy for symptomatic or complication-associated persistent tertiary hyperparathyroidism is usually parathyroidectomy. Surgical removal of hyperfunctioning tissue has the highest chance of cure.

Why the others are less appropriate:
- Conservative observation is inappropriate with complications (stones, low BMD) and persistent hypercalcaemia.
- Oral phosphate is not a recommended long-term strategy for tertiary hyperparathyroidism and can cause GI side effects and soft-tissue calcification.
- High-dose calcitriol may worsen hypercalcaemia and is not appropriate where hypercalcaemia is established from autonomous parathyroid secretion.
- IV bisphosphonates treat hypercalcaemia temporarily and address bone resorption, but they are not a definitive therapy for autonomous parathyroid tissue; they also carry caution in renal impairment and transplant patients.

A commonly used albumin-correction approximation in SI units is to add 0.02 mmol/L to the total calcium for each 1 g/L decrease in albumin below 40 g/L. Here albumin is 20 g/L (20 g/L below 40), so correction = 0.02 × 20 = 0.40 mmol/L. Corrected calcium = 2.20 + 0.40 = 2.60 mmol/L.

Why the others are less appropriate:
- 2.00 and 1.80 mmol/L would represent lower corrected calcium and imply no correction or incorrect direction of correction.
- 3.00 mmol/L is an overestimate given the formula above.
- While ionised calcium is the definitive measure of biologically active calcium and should be used when available or in critical situations, the albumin correction provides a pragmatic estimate and is commonly used in outpatient practice.

Note: albumin-correction formulas are approximations and less reliable in acutely ill patients or with abnormal protein states; ionised calcium measurement is preferable if clinical suspicion is high.

This clinical picture is most consistent with adynamic bone disease: low PTH, low bone turnover and a propensity for vascular calcification. Management aims to avoid further suppression of bone turnover and reduce calcium loading. Practical steps include stopping calcium-containing phosphate binders, avoiding high-dose active vitamin D and considering a lower-dialysate calcium to minimise calcium exposure.

Why the others are less appropriate:
- Increasing active vitamin D will further suppress PTH and may worsen adynamic bone disease and vascular calcification.
- Bisphosphonates are generally avoided in adynamic bone disease because they may further suppress bone turnover.
- Aluminium binders are not recommended due to aluminium toxicity and are inappropriate.
- Parathyroidectomy is indicated for refractory high PTH, not for low PTH states.

Cinacalcet is a calcimimetic that lowers PTH by increasing the sensitivity of the calcium-sensing receptor; it commonly causes or aggravates hypocalcaemia. A baseline corrected calcium of 1.95 mmol/L with symptoms of hypocalcaemia is a contraindication or strong reason to avoid starting cinacalcet until hypocalcaemia is corrected. Patients must have adequate baseline calcium and be monitored closely.

Why the others are less appropriate:
- Very high PTH with borderline calcium is a common indication for cinacalcet (after addressing reversible factors).
- Hyperphosphataemia is not a contraindication; phosphate control should be optimised but does not preclude cinacalcet.
- High alkaline phosphatase may reflect high bone turnover and does not contraindicate cinacalcet.
- Mild peptic ulcer disease is not an absolute contraindication; dose adjustments and monitoring for GI side effects may be required.

In patients with advanced CKD and evidence of vascular calcification, non-calcium-containing phosphate binders (sevelamer, lanthanum) are preferred to avoid further calcium loading that could exacerbate vascular calcification. KDIGO guidance suggests limiting calcium-based binders in those at risk of vascular calcification.

Why the others are less appropriate:
- Calcium-containing binders increase total calcium load and may worsen vascular calcification.
- Aluminium binders are discouraged because of risk of aluminium accumulation and toxicity, especially with long-term use.
- Delaying binder therapy until eGFR <15 ml/min ignores progressive hyperphosphataemia which should be addressed earlier when appropriate. - High-dose oral vitamin D will not lower phosphate and may increase calcium; it is not a strategy to reduce phosphate burden.

Third-generation PTH assays are designed to measure predominantly full-length 1-84 PTH and reduce cross-reactivity with large C-terminal fragments that accumulate in renal failure. This can yield values that more closely reflect biologically active hormone. However, while third-generation assays reduce fragment interference, they do not remove the need for clinical correlation and additional investigations (imaging, assessment of mineral metabolism) when managing hyperparathyroidism.

Why the others are less appropriate:
- Statement that they measure total PTH including many fragments is incorrect; that describes older assays' limitations.
- They are not identical to second-generation assays; second-generation 'intact' assays detect some fragments (e.g. 7-84) leading to potential differences in CKD.
- It is incorrect to state they are unaffected by renal failure—CKD still affects PTH physiology and fragments to some extent; assay performance improves specificity but clinical interpretation remains necessary.
- They do not eliminate the need for clinical correlation and imaging; biochemical assays are one component of assessment.